On September 14, Tempus AI rose 5.41% in regular trading, trading at $62.13/share with turnover of approximately $165 million, extending gains following a series of positive developments.

On the news front, Tempus AI announced it is building a research platform comprising 100,000 whole genome sequences paired with longitudinal clinical data, with a long-term goal of expanding to 1 million genomes. The dataset will be integrated into the company's existing de-identified multimodal platform, enabling researchers to access genomic information alongside clinical histories, imaging, pathology, and patient outcomes. General availability is planned for mid-2027.

Additionally, the company was selected by the Advanced Research Projects Agency for Health to receive up to $9.5 million to develop an autonomous clinical AI agent for heart-failure care, building on existing products including Olivia, Tempus Next, and three FDA-cleared ECG-AI products. These catalysts follow several analyst initiations, including Cantor Fitzgerald at Overweight with an $80 price target and UBS at Neutral with a $70 target, both above the current trading level.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)